Renal Cell Carcinoma
News
Exelixis seeks expanded indication for cabozantinib in RCC
The supplemental New Drug Application is based on results from the CABOSUN trial.
News
FDA advisory committee to consider adjuvant sunitinib for RCC
Phase 3 results for sunitinib as adjuvant treatment for high risk RCC have been mixed.
From the Journals
Sequential pazopanib and everolimus nets good survival in metastatic RCC
Sequential treatment with pazopanib and everolimus yields a median overall survival exceeding 2 years in predominantly older and sicker patients...
From the Journals
No survival benefit with adjuvant girentuximab in high-risk RCC
Adjuvant therapy with girentuximab failed to improve either disease-free or overall survival, compared with placebo, in a cohort of patients in...
From the Journals
Savolitinib improves PFS in some with MET-driven papillary renal cell carcinoma
Savolitinib, a highly selective inhibitor of c-Met receptor tyrosine kinase, improved progression-free survival in a small portion of patients...
Conference Coverage
PROTECT: Pazopanib falls short as adjuvant therapy for high-risk RCC
CHICAGO – In a phase III randomized controlled trial of more than 1,500 patients who had undergone nephrectomy for high-risk locally advanced RCC...
Conference Coverage
Immune-agonist combo has activity against several tumor types
CHICAGO – How can we improve responses in heavily pretreated patients with a variety of tumor types?
From the Journals
Alternating therapy in renal cell carcinoma fails to show an advantage
Everolimus alternating with pazopanib and pazopanib alone were compared in a randomized, multicenter controlled trial.
From the Journals
Novel agent varlilumab shows activity in RCC
A total of eight patients achieved stable disease in the phase I study, including four with RCC.
Conference Coverage
Debulking called reasonable for unresectable liver cancer
When advanced neuroendocrine liver cancer is unresectable, is debulking an appropriate option?
From the Journals
Metformin linked with better survival in RCC patients with diabetes
A meta-analysis of eight studies including 254,329 patients found better survival with metformin use.